Dr Reddy’s Laboratories has received approval from the US health regulator for drug that reduces blood phenylalanine concentrations in patients.
It has received tentative approval from US Food and Drug Administration for Sapropterin Dihydrochloride (100 mg) tablets.
Moreover, it has also launched Melphalan Hydrochloride for injection, a therapeutic equivalent generic version of Alkeran, in the US market in this week.
